Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCavis(TM) #cancer #heartdisease #inflammation #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals

First pipeline asset from Yellowbird's platform to enter clinical development Phase I trial evaluating NeuCaVis™ in healthy volunteers Phase I completion anticipated June 2026 Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation.To view an enhanced version of...


http://dlvr.it/TS3CQW

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

ASTRA TT Signs Strategic MOU with India's BIS to Accelerate Green Charging Infrastructure Across the Nation #Publishing #Technology